Bendamustine, bortezomib and rituximab produces durable complete remissions in patients with previously untreated, low grade lymphoma by Flinn, Ian W., Thompson, Dana S., Boccia, Ralph V., Miletello, Gerald, Lipman, Andrew, Flora, Douglas, Cuevas, Daniel, Papish, Steven W., Berdeja, Jesus G.

Get full text

Abstract P2-13-21: Improved central nervous system outcomes in patients with early-stage HER2-positive breast cancer who receive neratinib for the recommended duration: Findings fr... by Holmes, Frankie Ann, Patt, Debra, Manalo, Yvonne, Smith, Julie C, Papish, Steven W, Efrat, Noa, Arance, Ana, Zhang, Bo, Lalla, Deepa, Wong, Alvin, Martin, Miguel

Get full text

Randomized Phase 2 Open-Label Study of R-CHOP ± Bortezomib in Patients (Pts) with Untreated Non-Germinal Center B-Cell-like (Non-GCB) Subtype Diffuse Large Cell Lymphoma (DLBCL): R... by Leonard, John P., Kolibaba, Kathryn, Reeves, James A., Tulpule, Anil, Flinn, Ian W., Kolevska, Tatjana, Robles, Robert, Flowers, Christopher, Collins, Robert, DiBella, Nicholas J., Papish, Steven W., Venugopal, Parameswaran, Horodner, Andrew, Tabatabai, Amir, Hajdenberg, Julio, Mulligan, George, Neuwirth, Rachel, Suryanarayan, Kaveri, Esseltine, Dixie-Lee, de Vos, Sven

Get full text

Phase II Trial of Ofatumumab (OFA) for Older Patients and Patients Who Refuse Fludarabine-Based Regimens with Previously Untreated Chronic Lymphocytic Leukemia (CLL) or Small Lymph... by Flinn, Ian W., Harwin, William N., Ward, Patrick, Doss, Habib H., Papish, Steven W., Hainsworth, John D., Berdeja, Jesus G., Byrd, John C.

Get full text

Bendamustine, Bortezomib, and Rituximab in Patients with Previously Untreated Low Grade Lymphoma: A Phase II Trial of the Sarah Cannon Research Institute by Flinn, Ian W., Thompson, Dana S., Boccia, Ralph V., Miletello, Gerald, Lipman, Andrew, Flora, Douglas, Cuevas, Daniel, Papish, Steven W., Berdeja, Jesus G.

Get full text

A Phase II Trial of Ofatumumab for Older Patients and Patients Who Refuse Fludarabine-Based Regimens with Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lym... by Flinn, Ian W., Harwin, William N., Macias-Pérez, Inés M., Tucker, Patrick S., Waterhouse, David M., Papish, Steven W., Jones, Jeffrey A., Hainsworth, John D., Byrd, John C.

Get full text

Rapid Prospective Identification of Non-Germinal Center B Cell-Like (GCB) Diffuse Large B-Cell Lymphoma (DLBCL) Patients for Targeted Trials: Early Results From PYRAMID, A Phase 2... by Doner, Kevin, Flinn, Ian W., Ulrich, Brian K., Noga, Stephen J., Chowhan, Naveed M., Papish, Steven W., Mahmood, Tallat, Reeves, James A, Bella, Nicholas J. Di, Robbins, Gerald J., Ramchandren, Radhakrishnan, Aung, Sein, Lawler, William, Parasuraman, Sudha, Corvez, Maria M., Mulligan, George, Leonard, John P.

Get full text

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial by Iwata, Hiroji, Chia, Stephen K L, Bashford, Anna, Inoue, Kenichi, Armstrong, Anne C, Wong, Alvin, Buyse, Marc, Harvey, Vernon, Smith, John W., Konstantinovic, Zora Neskovic, Rodriguez, Gladys I., Jáñez Martinez, Noelia, Knoop, Ann Soegaard, De Boer, Richard Hendry, Rai, Yoshiaki, Yamamoto, Naohito, Brincat, Stephen, Papish, Steven William, Manalo, Yvonne, Sorensen, Peter Grundtvig, Aogi, Kenjiro, Shimizu, Satoru, Mainwaring, Paul, Chang, Jose, del Barco Berron, Sonia, Dickerson, Laura C., Klein, Leonard M., Ruxer, Robert, Veyret, Corinne, Wagnerova, Maria, Richards, Donald A., Vasileios, Asskikis, Dourthe, Louis Marie, Lu, Yen-Shen, Greenspan, Andrew R., Gonzalez Santiago, Santiago, Perren, Timothy John, Yau, Chung Cheung Thomas, Pikó, Béla, Sato, Nobuaki, Askoy, Sercan, Altundag, Mustafa Kadri, Saip, Pinar, Bajaj, Rajesh, Vestlev, Peter Michael, Dank, Magdolna, Cinieri, Saverio, Suszko-Kazarnowicz, Malgorzata, Yap, Yoon Sim, Chen, Shin-Cheh, Haley, Barbara Bacsik, Inhorn, Roger C., Koynova, Tatyana, Schneeweiss, Andreas, Cubedo Cervera, Ricardo, Urruticoechea Ribate, Ander, Schwartz, Garry H., Mocharnuk, Robert Scott, Alkhouri, Nabiel, Erickson, Nicholette, Traynor, Ann, Volterra, Fabio, Capo, Gerardo, Flaherty, Lawrence E., Baidas, Said, Lybaert, Willem, Holland, David R., Gonzalez Jimenez, Sonia, Vanlemmens, Laurence, Ruggeri, Enzo Maria, Desai, Ajit, Nixon, David Allen, O'Brien, Edward, Lanier, Keith S., Brescia, Frankie Ann, Richard, Vincent, Geldhof, Kurt, Bednarik, Otakar, Schwedler, Kathrin, Fries, Stefan, Klare, Peter, Griesinger, Frank, Trufflandier, Nathalie, Chetiyawardana, Anula D., Papandreou, Christos, Hornyak, Lajos, Simo, Erzsebet, Im, Seock-Ah, Ruit, Jan B., Ciltas, Aydin, Benekli, Mustafa, Conkright, William A., Ottaviano, Yvonne, Delmas, Andrew, Steele, Heather A., Bova, Abby R., Shirinian, Mihran, O'Rourke, Timothy J., Francisco, Michael, Carrillo Flores, Maria Regina

Get full text

Synthesis of Biomimetic Zinc Complexes for CO2 Activation and the Influence of Steric Changes in the Ttz Ligands [Ttz = Tris(triazolyl)borate] by Siek, Sopheavy, Dixon, Natalie A., Kumar, Mukesh, Kraus, Jodi S., Wells, Kirsten R., Rowe, Brittany W., Kelley, Steven P., Zeller, Matthias, Yap, Glenn P. A., Papish, Elizabeth T.

Get full text

A phase II study of two dose levels of ofatumumab induction followed by maintenance therapy in symptomatic, previously untreated chronic lymphocytic leukemia by Flinn, Ian W., Ruppert, Amy S., Harwin, William, Waterhouse, David, Papish, Steven, Jones, Jeffrey A., Hainsworth, John, Byrd, John C.

Get full text